Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Gilead Sciences Inc (GILD)

Gilead Sciences Inc (GILD)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 84,074,120
  • Shares Outstanding, K 1,253,528
  • Annual Sales, $ 22,449 M
  • Annual Income, $ 5,386 M
  • 60-Month Beta 0.51
  • Price/Sales 3.65
  • Price/Cash Flow 8.68
  • Price/Book 4.54
Trade GILD with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 21 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/20
See More
  • Average Estimate 1.98
  • Number of Estimates 11
  • High Estimate 2.25
  • Low Estimate 1.64
  • Prior Year 1.10
  • Growth Rate Est. (year over year) +80.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
56.56 +20.21%
on 12/31/20
68.16 -0.25%
on 01/19/21
+8.91 (+15.08%)
since 12/18/20
3-Month
56.56 +20.21%
on 12/31/20
68.16 -0.25%
on 01/19/21
+7.44 (+12.29%)
since 10/20/20
52-Week
56.56 +20.21%
on 12/31/20
85.97 -20.91%
on 03/19/20
+5.01 (+7.95%)
since 01/17/20

Most Recent Stories

More News
Precision BioSciences' (DTIL) New Lymphoma Drug IND Gets FDA Nod

The FDA accepts Precision BioSciences' (DTIL) regulatory application to initiate a clinical study on its next-generation CD19 product candidate, PBCAR19B.

GILD : 67.99 (+1.37%)
LLY : 201.26 (+1.40%)
HALO : 47.67 (-1.24%)
DTIL : 14.64 (unch)
Worldwide Pulmonary Arterial Hypertension Industry to 2025 - Featuring Gilead Sciences, United Therapeutics and Novartis International Among Others

The "Global Pulmonary Arterial Hypertension (2020-2025) by Drug Class, Route of Administration, Distribution Mode, Geography, Competitive Analysis and the Impact of Covid-19 with Ansoff Analysis" report...

GILD : 67.99 (+1.37%)
UTHR : 171.17 (-0.26%)
Gilead Sciences Down 40.7% Since SmarTrend Downtrend Call (GILD)

SmarTrend identified a Downtrend for Gilead Sciences (NASDAQ:GILD) on July 8th, 2015 at $113.41. In approximately 67 months, Gilead Sciences has returned 40.68% as of today's recent price of $67.28.

GILD : 67.99 (+1.37%)
Francesco M. Marincola Joins Kite as Worldwide Head of Cell Therapy Research

Kite, a Gilead Company (Nasdaq: GILD), today announced that Francesco Marincola, MD, will join the company as Senior Vice President and Global Head of Cell Therapy Research, effective February 1. Dr. Marincola...

GILD : 67.99 (+1.37%)
Vera Therapeutics Launches with $80 Million Series C Financing to Develop Phase 2b Novel Biologic for Kidney Disease

, /PRNewswire/ -- Vera Therapeutics, Inc., a clinical-stage biotechnology company focused on developing treatments for immunological and inflammatory diseases, today announced its launch backed by Series...

GILD : 67.99 (+1.37%)
What's in Store for UnitedHealth (UNH) This Earnings Season?

UnitedHealth's (UNH) earnings results are likely to reflect solid contribution from its segments, namely Healthcare and Optum, partly offset by higher claim costs.

UNH : 350.84 (-0.38%)
GILD : 67.99 (+1.37%)
ABT : 112.89 (+0.28%)
ANTM : 321.52 (-0.67%)
Gilead Sciences (GILD) Gains As Market Dips: What You Should Know

Gilead Sciences (GILD) closed at $63.33 in the latest trading session, marking a +1.49% move from the prior day.

GILD : 67.99 (+1.37%)
Gilead Sciences Rises 1.19% on Heavy Volume: Watch For Potential Pullback

Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $62.17 to a high of $63.28. Yesterday, the shares gained 1.2%, which took the trading range above the 3-day high of...

GILD : 67.99 (+1.37%)
Watch for Gilead Sciences to Potentially Pullback After Gaining 1.19% Yesterday

Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $62.17 to a high of $63.28. Yesterday, the shares gained 1.2%, which took the trading range above the 3-day high of...

GILD : 67.99 (+1.37%)
Gilead Sciences Set to Possibly Pullback After Yesterday's Rally of 1.19%

Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $62.17 to a high of $63.28. Yesterday, the shares gained 1.2%, which took the trading range above the 3-day high of...

GILD : 67.99 (+1.37%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The Company strive to transform and simplify care for people with life-threatening illnesses around the world. Gilead's portfolio of products...

See More

Key Turning Points

3rd Resistance Point 69.88
2nd Resistance Point 68.98
1st Resistance Point 68.49
Last Price 67.99
1st Support Level 67.10
2nd Support Level 66.20
3rd Support Level 65.71

See More

52-Week High 85.97
Fibonacci 61.8% 74.74
Fibonacci 50% 71.26
Last Price 67.99
Fibonacci 38.2% 67.79
52-Week Low 56.56

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar